A new study states that there is no compelling evidence justifying using drug therapy to suppress their testosterone production for men with early-stage prostate cancer which have been used for decades while introducing many unpleasant side effects. The analysis states that there is no evidence that androgen deprivation therapy extends the life of these patients. The attached editorial, written by physicians at the Dana-Farber Cancer Institute in Boston, summarizes the analysis regarding the new philosophy on using drugs to diminish testosterone production for early-stage prostate cancer patients which it recommends for inclusion in the “Choosing Wisely” campaign by the American Board of Internal Medicine Foundation to warn doctors and patients about unnecessary medical tests and procedures.
Hormone Therapeutics July 24th, 2014
Posted In: Testosterone Therapy